Comparative Pharmacology
Head-to-head clinical analysis: AMICAR versus AMINOCAPROIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMICAR versus AMINOCAPROIC.
AMICAR vs AMINOCAPROIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by blocking the binding of plasminogen to fibrin.
Competitive inhibition of plasminogen activation and, to a lesser extent, noncompetitive inhibition of plasmin, thereby preventing fibrinolysis and promoting clot stability.
4-5 g IV loading dose over 1 hour, followed by 1 g/hour IV continuous infusion for 8 hours or until bleeding controlled; oral: 5 g PO initially, then 1-1.25 g PO every hour as needed.
4-5 g orally or intravenously as a loading dose, followed by 1 g/hour continuous infusion or 1 g every 4-6 hours orally. Maximum dose 30 g/day.
None Documented
None Documented
Clinical Note
moderateAminocaproic acid + Tretinoin
"Aminocaproic acid may increase the thrombogenic activities of Tretinoin."
Terminal elimination half-life: 2 hours (range 1-3.5 hours). After high doses or renal impairment, half-life may prolong (up to 5-10 hours).
Terminal elimination half-life: 2 hours (normal renal function); prolonged to 4–10 hours in renal impairment. Clinically, dosing interval must be adjusted in renal dysfunction to avoid accumulation.
Renal: >99% of absorbed dose excreted unchanged in urine. Biliary/fecal: negligible (<1%).
Primarily renal (>95%) as unchanged drug via glomerular filtration and tubular secretion. Less than 1% biliary/fecal.
Category C
Category C
Antifibrinolytic
Antifibrinolytic